Dr. Longzhu Cui is a physician-scientist and professor of microbiology whose research focuses on bacteriophage biology, antimicrobial resistance, and the development of innovative phage-based therapeutic technologies. After obtaining his medical doctorate and clinical training, he transitioned into academic research that bridges clinical relevance with cutting-edge biomedical innovation.////
His work has led to pioneering advancements, including the isolation of broad-host-range Staphylococcus aureus phages, the development of DNA-free engineered phage capsids for targeted drug delivery and cancer therapy, and the construction of CRISPR-Cas13a-based phage systems for gene-specific reversal of antibiotic resistance. He plays a leading role in nationally funded projects such as AMED-CREST and JSPS KAKENHI (Scientific Research A and Challenging Research (Pioneering)), and is actively involved in intellectual property development and international collaboration.////
As an editorial board member for MDPI journals and a frequent invited speaker at academic conferences, Dr. Cui continues to advance the field of phage therapeutics and translational microbiology, both in Japan and internationally.
Dr. Longzhu Cui is a physician-scientist and professor of microbiology whose research focuses on bacteriophage biology, antimicrobial resistance, and the development of innovative phage-based therapeutic technologies. After obtaining his medical doctorate and clinical training, he transitioned into academic research that bridges clinical relevance with cutting-edge biomedical innovation.////
His work has led to pioneering advancements, including the isolation of broad-host-range Staphylococcus aureus phages, the development of DNA-free engineered phage capsids for targeted drug delivery and cancer therapy, and the construction of CRISPR-Cas13a-based phage systems for gene-specific reversal of antibiotic resistance. He plays a leading role in nationally funded projects such as AMED-CREST and JSPS KAKENHI (Scientific Research A and Challenging Research (Pioneering)), and is actively involved in intellectual property development and international collaboration.////
As an editorial board member for MDPI journals and a frequent invited speaker at academic conferences, Dr. Cui continues to advance the field of phage therapeutics and translational microbiology, both in Japan and internationally.